| Autor: |
Mitsuhiro Iyori, Daisuke S. Yamamoto, Miako Sakaguchi, Masanori Mizutani, Sota Ogata, Hidesato Nishiura, Takahiko Tamura, Hiroyuki Matsuoka, Shigeto Yoshida |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Malaria Journal, Vol 16, Iss 1, Pp 1-10 (2017) |
| Druh dokumentu: |
article |
| ISSN: |
1475-2875 |
| DOI: |
10.1186/s12936-017-2039-x |
| Popis: |
Abstract Background Previous studies have shown that the baculovirus-vectored vaccine based on the “baculovirus dual expression system (BDES)” is an effective vaccine delivery platform for malaria. However, a point of weakness remaining for use of this vaccine platform in vivo concerns viral inactivation by serum complement. In an effort to achieve complement resistance, the gene encoding the human decay-accelerating factor (hDAF) was incorporated into the BDES malaria vaccine expressing the Plasmodium falciparum circumsporozoite protein (PfCSP). Results The newly-developed BDES vaccine, designated BDES-sPfCSP2-Spider, effectively displayed hDAF and PfCSP on the surface of the viral envelope, resulting in complement resistance both in vitro and in vivo. Importantly, upon intramuscular inoculation into mice, the BDES-sPfCSP2-Spider vaccine had a higher protective efficacy (60%) than that of the control vaccine BDES-sPfCSP2-Spier (30%) against challenge with transgenic Plasmodium berghei sporozoites expressing PfCSP. Conclusion DAF-shielded BDES-vaccines offer great potential for development as a new malaria vaccine platform against the sporozoite challenge. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
